0.05
+0(+0.00%)
Currency In CAD
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
8
First IPO Date
February 15, 2012
| Name | Title | Pay | Year Born |
| Dr. Sabine Mai Ph.D. | Founder, Interim Chief Executive Officer, Chair of the Clinical & Scientific Advisory Board and Director | 35,000 | N/A |
| Mr. Christopher Ross CPA, CGA | Chief Financial Officer | 60,000 | N/A |
| Mr. Guido Baechler | Executive Chairman | 98,207 | 1965 |
| Dr. Hans Knecht M.D. | Medical laboratory Director & Member of Clinical Advisory Board | 0 | N/A |
| Dr. Mark Stene M.B.A., Ph.D. | Head of Laboratory Operations | 0 | N/A |
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.